News | November 10, 2022
AGC to establish Life Science Company in 2023
The Group will continue to make proactive investments of its management resources in the life science business
The Group will continue to make proactive investments of its management resources in the life science business
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
An RMAT confers eligibility for accelerated approval and priority review of biologics licensing applications (BLA)
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Researchers from the Tel Aviv University successfully engineer the world's first 3D human spinal cord tissue transplant
Essent continues to broaden its highly characterized, low passage primary cell catalog
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Subscribe To Our Newsletter & Stay Updated
